Literature DB >> 22623223

The effects of continuing and discontinuing smoking on the development of chronic kidney disease (CKD) in the healthy middle-aged working population in Japan.

Yuka Noborisaka1, Masao Ishizaki, Yuichi Yamada, Ryumon Honda, Hitoshi Yokoyama, Masaru Miyao, Masaji Tabata.   

Abstract

OBJECTIVES: The strength of the association between smoking and the development of chronic kidney disease (CKD) in the healthy middle-aged working age population has not been established.
METHODS: This was a retrospective 6-year observational study involving 4,121 male and 2,877 female workers who were free of primary kidney disease, diabetes mellitus, severe hypertension, and the signs and symptoms of CKD. Proteinuria was detected by a dipstick method, and glomerular filtration rate (GFR) was estimated by the equation of the Japan Society of Nephrology.
RESULTS: Sixty men (1.5 %) and 21 women (0.7 %) developed proteinuria over the 6 years of the study. Irrespective of sex, in comparison with non-smokers, those who continued smoking showed an odds ratio (OR) of 2.52 with a 95 % confidence interval (CI) of 1.50-4.25 for developing proteinuria while those who quit smoking showed an OR of 1.29 (95 % CI 0.48-3.42), following adjustment for confounders. Among the study population, 443 men (10.7 %) and 356 women (12.4 %) developed a GFR of <60 mL/min/1.73 m(2), corresponding to stage III CKD. Continuing smokers had a low OR (0.74, 95 % CI 0.60-0.90) for developing a low GFR, as well as a higher mean GFR than non-smokers. The reduction in GFR during the 6-year study period was not different between smokers and non-smokers, but it was larger in those who developed proteinuria than in those who did not, irrespective of smoking.
CONCLUSIONS: Continuing smokers showed a twofold or more higher risk of developing proteinuria. Discontinuation of smoking substantially reduced the risk. A longer observational period may be required to detect the smoking-induced risk of developing stage III CKD in the middle-aged working population.

Entities:  

Mesh:

Year:  2012        PMID: 22623223      PMCID: PMC3541810          DOI: 10.1007/s12199-012-0285-7

Source DB:  PubMed          Journal:  Environ Health Prev Med        ISSN: 1342-078X            Impact factor:   3.674


  34 in total

Review 1.  Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence?

Authors:  Stephan R Orth; Stein I Hallan
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-14       Impact factor: 8.237

Review 2.  The renal risks of smoking.

Authors:  S R Orth; E Ritz; R W Schrier
Journal:  Kidney Int       Date:  1997-06       Impact factor: 10.612

3.  Relationship between estimated glomerular filtration rate (eGFR) and metabolic syndrome in Japanese.

Authors:  Nobuyuki Miyatake; Kenichi Shikata; Hirofumi Makino; Takeyuki Numata
Journal:  Acta Med Okayama       Date:  2010-06       Impact factor: 0.892

Review 4.  Effect of heavy metals on, and handling by, the kidney.

Authors:  Olivier Barbier; Grégory Jacquillet; Michel Tauc; Marc Cougnon; Philippe Poujeol
Journal:  Nephron Physiol       Date:  2005-02-17

Review 5.  Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis.

Authors:  Paul E Ronksley; Susan E Brien; Barbara J Turner; Kenneth J Mukamal; William A Ghali
Journal:  BMJ       Date:  2011-02-22

6.  The differential effect of cigarette smoking on glomerular filtration rate and proteinuria in an apparently healthy population.

Authors:  Hyung-Jin Yoon; Minseon Park; Hyeongseok Yoon; Ki-Young Son; Belong Cho; Suhnggwon Kim
Journal:  Hypertens Res       Date:  2009-01-30       Impact factor: 3.872

7.  Effects of smoking on renal hemodynamics in healthy volunteers and in patients with glomerular disease.

Authors:  E Ritz; U Benck; E Franek; C Keller; M Seyfarth; J Clorius
Journal:  J Am Soc Nephrol       Date:  1998-10       Impact factor: 10.121

8.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

Review 9.  Cigarette smoking and incident chronic kidney disease: a systematic review.

Authors:  Charlotte Jones-Burton; Stephen L Seliger; Roberta W Scherer; Shiraz I Mishra; Ghazal Vessal; Jeanine Brown; Matthew R Weir; Jeffrey C Fink
Journal:  Am J Nephrol       Date:  2007-05-23       Impact factor: 3.754

Review 10.  Adverse health effects of chronic exposure to low-level cadmium in foodstuffs and cigarette smoke.

Authors:  Soisungwan Satarug; Michael R Moore
Journal:  Environ Health Perspect       Date:  2004-07       Impact factor: 9.031

View more
  11 in total

Review 1.  The Lifelong Health Support 10: a Japanese prescription for a long and healthy life.

Authors:  Ahmed Arafa; Yoshihiro Kokubo; Rena Kashima; Masayuki Teramoto; Yukie Sakai; Saya Nosaka; Youko M Nakao; Emi Watanabe
Journal:  Environ Health Prev Med       Date:  2022       Impact factor: 4.395

2.  Distribution of and factors contributing to chronic kidney disease in a middle-aged working population.

Authors:  Yuka Noborisaka; Masao Ishizaki; Yuichi Yamada; Ryumon Honda; Hitoshi Yokoyama; Masaru Miyao; Masaji Tabata
Journal:  Environ Health Prev Med       Date:  2013-06-02       Impact factor: 3.674

Review 3.  Hypoxia: The Force that Drives Chronic Kidney Disease.

Authors:  Qiangwei Fu; Sean P Colgan; Carl Simon Shelley
Journal:  Clin Med Res       Date:  2016-02-04

4.  Impacting incidence of disease through population-based interventions: Appraisal of the ARIC study findings.

Authors:  Sabine Karam
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-05-23       Impact factor: 3.738

5.  Modifiable Lifestyle Factors for Primary Prevention of CKD: A Systematic Review and Meta-Analysis.

Authors:  Jaimon T Kelly; Guobin Su; Xindong Qin; Skye Marshall; Ailema González-Ortiz; Catherine M Clase; Katrina L Campbell; Hong Xu; Juan-Jesus Carrero
Journal:  J Am Soc Nephrol       Date:  2020-08-31       Impact factor: 10.121

6.  Elevated Blood Pressure and Serum γ -Glutamyltransferase as Significant Characteristics of Smokers With Chronic Kidney Disease.

Authors:  Yuka Noborisaka; Masao Ishizaki; Michiko Yamazaki; Ryumon Honda; Yuichi Yamada
Journal:  Nephrourol Mon       Date:  2014-07-05

7.  Associations of smoking with cardiometabolic profile and renal function in a Romanian population-based sample from the PREDATORR cross-sectional study.

Authors:  Simona Georgiana Popa; Maria Moţa; Florin Dumitru Mihălţan; Adina Popa; Ioana Munteanu; Eugen Moţa; Cristian Serafinceanu; Cristian Guja; Nicolae Hâncu; Doina Catrinoiu; Radu Lichiardopol; Cornelia Bala; Bogdan Mihai; Gabriela Radulian; Gabriela Roman; Romulus Timar
Journal:  Eur J Gen Pract       Date:  2017-12       Impact factor: 1.904

8.  Association between Overall Lifestyle Changes and the Incidence of Proteinuria: A Population-based, Cohort Study.

Authors:  Minako Wakasugi; Junichiro Kazama; Ichiei Narita; Kunitoshi Iseki; Shouichi Fujimoto; Toshiki Moriyama; Kunihiro Yamagata; Tsuneo Konta; Kazuhiko Tsuruya; Koichi Asahi; Masahide Kondo; Issei Kurahashi; Yasuo Ohashi; Kenjiro Kimura; Tsuyoshi Watanabe
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

9.  Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney.

Authors:  Xiangling Wang; Terri J Vrtiska; Ramesh T Avula; Leah R Walters; Harini A Chakkera; Walter K Kremers; Lilach O Lerman; Andrew D Rule
Journal:  Kidney Int       Date:  2013-09-25       Impact factor: 10.612

Review 10.  Behavioural Risk Factors in Mid-Life Associated with Successful Ageing, Disability, Dementia and Frailty in Later Life: A Rapid Systematic Review.

Authors:  Louise Lafortune; Steven Martin; Sarah Kelly; Isla Kuhn; Olivia Remes; Andy Cowan; Carol Brayne
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.